Why is AnaptysBio stock rising afterhours today?
AnaptysBio Inc stock increased by 3.8% in after-hours trading following the company's announcement of positive second-quarter and transitional fiscal year 2026 financial results. The San Diego-based biotech firm reported revenue of $27.5 million, which exceeded expectations by more than 36%, surpassing the estimated $20 million.
CEO Daniel Faga expressed optimism regarding the company's future prospects, citing potential near-term value catalysts in his earnings release. These catalysts include accelerated sales of Jemperli outside the U.S., an expected FDA approval of Jemperli as a monotherapy for a specific type of rectal cancer, a looming litigation judgment against GSK and Tesaro, and a projected FDA approval of Quimilza in a specific condition by December 2026.
The positive market sentiment also contributed to the stock's rise, as Wall Street experienced a surge earlier in the week, bolstered by the performance of tech shares.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
